Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Urol Oncol. 2021 Jan 19;39(8):493.e9–493.e15. doi: 10.1016/j.urolonc.2020.11.038

Figure 2: Mean predicted decisional regret score for cases that chose active surveillance or definite treatment, and (A) by race (black vs others), (B) by hormonal symptom at 6-month (presence vs absence), (C) by bowel symptom at 6-month (presence vs absence).

Figure 2:

Note: P3P=Personal Patient Profile-Prostate; UC=Usual Care EPIC-CP=Expanded Prostate Cancer Index Composite-Clinical Practice; Surv=Surveillance; Tx=Treatment